GSK_ Annual_Report_2021-22

115 Standalone Statement of Profit and Loss for the year ended March 31, 2022 ( ` in lakhs) Notes Year ended March 31, 2022 Year ended March 31, 2021 Continuing operations Income Revenue from operations 30 3217,50.87 2920,47.58 Other income 31 76,21.57 110,18.78 Total income 3293,72.44 3030,66.36 Expenses Cost of materials consumed 32 552,47.11 452,39.86 Purchases of stock-in-trade 32 729,44.10 823,09.06 Changes in inventories of finished goods, stock-in-trade and work-in-progress 33 13,82.60 (26,12.38) Employee benefits expense 34 610,23.13 616,16.01 Finance costs 35 1,98.98 3,53.14 Depreciation and amortization expense 36 68,18.60 78,60.49 Other expenses 37 555,71.25 457,17.65 Total expenses 2531,85.77 2404,83.83 Profit before exceptional items and tax 761,86.67 625,82.53 Exceptional items (net) 40 11,57.66 (172,59.69) Profit before tax 773,44.33 453,22.84 Tax expense: 47 Current tax 219,42.59 158,67.23 Deferred tax (10,49.39) 7,86.69 Tax adjustment of earlier years 187,93.59 - 396,86.79 166,53.92 Profit for the year from continuing operations 376,57.54 286,68.92 Discontinued Operations 55 Profit before tax from discontinued operations 1708,17.66 96,50.78 Tax expense of discontinued operations 394,22.62 25,62.94 Profit from discontinued operations (after tax) 1313,95.04 70,87.84 Profit for the year 1690,52.58 357,56.76 Other comprehensive (loss) Items that will not be reclassified to profit or loss Remeasurement of defined benefit plans 47 (2,46.59) (2,73.74) Income tax relating to items that will not be reclassified to profit or loss 47 62.06 68.90 (1,84.53) (2,04.84) Total comprehensive income for the year 1688,68.05 355,51.92 Earnings per equity share 49 Earnings per equity share from continuing operations Basic and diluted earnings per share before exceptional item 21.48 27.13 Basic and diluted earnings per share after exceptional item 22.23 16.92 Earnings per equity share from discontinued operations Basic and diluted earnings per share 77.56 4.18 Earnings per equity share from continuing operations & discontinued operations Basic and diluted earnings per share before exceptional item 99.05 31.32 Basic and diluted earnings per share after exceptional item 99.79 21.11 The accompanying notes 1 to 63 are an integral part of the Standalone Financial Statements In terms of our report attached For Deloitte Haskins & Sells LLP For and on behalf of the Board of Directors Chartered Accountants R. S. Karnad Chairperson DIN: 00008064 Firm‘s Registration No. 117366W/W-100018 S. Venkatesh Managing Director DIN: 07263117 J. Chandy CFO & Whole-time Director DIN: 09530618 Rupen K. Bhatt D. Sundaram Audit Committee Chairman DIN: 00016304 Partner A. Nadkarni Company Secretary FCS 10460 Membership No. 046930 Mumbai, May 16, 2022 Mumbai, May 16, 2022